Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 11/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213402 | 1.00 | GRIA4 (0.72) | GRIA4GRIA2KCNH2KDM1AMAOB | |
| SCHEMBL12513687 | 1.00 | GRIA4 (0.72) | GRIA4GRIA2KCNH2KDM1AMAOB | |
| SCHEMBL12513977 | 0.84 | GRIA4 (0.72) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4607668 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4608168 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4605805 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL6554606 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL5187459 | 0.81 | GRIA2 (0.67) | GRIA4GRIA2KCNH2 | |
| SCHEMBL5187456 | 0.81 | GRIA2 (0.67) | GRIA4GRIA2KCNH2 | |
| SCHEMBL5187467 | 0.81 | GRIA2 (0.67) | GRIA4GRIA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| EP-1848695-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006087169-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | GRIA4 18/4885GRIA2 17/4885KCNH2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.